The strong YORVIPATH growth and positive operating income signal a fundamental inflection point. Monitor Q2 2026 for initial YUVIWEL revenue and the PRV sale proceeds, which will further strengthen liquidity. The convertible note conversion eliminates $575M in debt, potentially improving equity quality.
Price Chart
Executive Summary
Ascendis Pharma reported Q1 2026 revenue of €246.6M (+144% YoY), driven by YORVIPATH sales tripling to €196.9M. Operating profit turned positive to €24.8M vs a loss of €104.2M, and net profit of €629.3M included a €679.0M deferred tax asset recognition. Subsequent events include FDA approval of YUVIWEL and a $187.5M PRV sale, strengthening the balance sheet.
Key Facts
- Revenue €246.6M, up 144% YoY (Q1 2025: €100.95M)
- Operating profit €24.8M vs loss of €104.2M YoY
- Net profit €629.3M (includes €679.0M deferred tax asset recognition)
- Basic EPS €10.20 vs -€1.58 YoY
- YORVIPATH revenue €196.9M, up 341% YoY
- Cash and cash equivalents €572.8M at March 31, 2026
- YUVIWEL (navepegritide) FDA approval for achondroplasia in February 2026
- Agreement to sell Rare Pediatric Disease PRV for $187.5M on May 6, 2026
- Completed conversion of $575M convertible notes into equity on May 6, 2026
Financial Impact
Revenue increased by €145.6M YoY; operating profit improved by €129.0M; net profit includes €679.0M non-cash deferred tax benefit
Risk Factors
- BioMarin patent litigation (ITC trial ongoing) could impact YUVIWEL commercialization
- Foreign exchange headwinds (USD/EUR volatility) may affect reported revenue
- Uncertainty around tariff measures on pharmaceutical products
- Sustained profitability depends on continued commercial execution for YORVIPATH and YUVIWEL
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001612042-26-000005 |
| Document: 0001612042-26-000005-index-headers.html | 0001612042-26-000005 |
| Document: 0001612042-26-000005-index.html | 0001612042-26-000005 |
| Document: 0001612042-26-000005.txt | 0001612042-26-000005 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access